Evidence map›Paper›PMID 31247511›Full record

ReviewBiomaterials2019

Bioinspired nucleic acid structures for immune modulation.

Cameron Louttit, Kyung Soo Park, James J Moon

Open access · greenAbstract readReview
In one paragraph

Review in Biomaterials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Engineering the Immune Response to Biomaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Cameron LouttitDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109, USA.
Kyung Soo ParkDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109, USA.
James J MoonDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109, USA; Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, 48109, USA. Electronic address: moonjj@umich.edu.
BioSurfaces (United States) · USUniversity of Michigan–Ann Arbor · US

Funding

Tissue Engineering and RegenerationT32DE007057 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID H. KOHN · 1985 to 2026
$17.3M
Cellular Biotechnology Training Program (CBTP)T32GM008353 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHWENDEMAN, ANNA · 1991 to 2021
$9.3M
Environmental Regulation of Cancer Stem Cell Plasticity in MetastasisU01CA210152 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LAHANN, JOERG, LUKER, GARY D · 2017 to 2021
$3.6M
Transfer Application - R01 CA223804 - Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung CancerR01CA223804 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI WANG, LI LILY, YOU, MING · 2018 to 2022
$3.3M
Cellular Biotechnology Training Program (CBTP) - Years 31-35T32GM145304 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Guizhi Zhu · 2022 to 2026
$2.6M
Elicitation of mucosal immune responses against HIVR01AI127070 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOON, JAMES J. · 2016 to 2020
$2.3M
Nanomaterials for eliciting anti-tumor T-cells-Diversity SupplementR01CA210273 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOON, JAMES J. · 2017 to 2021
$2.2M
Tuning Biomaterials-immune cell interactions for treatment of glioblastoma multiformeR01EB022563 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOON, JAMES J. · 2016 to 2019
$1.7M
NCI NIH HHS R01 CA210273NCI NIH HHS R01 CA223804NCI NIH HHS U01 CA210152NIAID NIH HHS R01 AI127070NIBIB NIH HHS R01 EB022563NIDCR NIH HHS T32 DE007057NIGMS NIH HHS T32 GM008353NIGMS NIH HHS T32 GM145304
6 · The paper itself

Abstract

Nucleic acids have both extensive physiological function and structural potential, rendering them quintessential engineering biomaterials. As carriers of precisely-tunable genetic information, both DNA and RNA can be synthetically generated to form a myriad of structures and to transmit specific genetic code. Importantly, recent studies have shown that DNA and RNA, both in their native and engineered forms, can function as potent regulators of innate immunity, capable of initiating and modulating immune responses. In this review, we highlight recent advances in biomaterials inspired by the various interactions of nucleic acids and the immune system. We discuss key advances in self-assembled structures based on exogenous nucleic acids and engineering approaches to apply endogenous nucleic acids as found in immunogenic cell death and extracellular traps. In addition, we discuss new strategies to control dinucleotide signaling and provide recent examples of biomaterials designed for cancer immunotherapy with STING agonists.

Indexed as

BiomimeticsImmunomodulationAnimalsHumansLiposomesNucleic AcidsPolymersSecond Messenger SystemsLiposomesNucleic AcidsPolymersHydrogelsImmune activationImmunoengineeringImmunotherapyLiposomesNanoparticles

Identifiers

PMID31247511
PMCPMC6635102
OpenAlexW2951467355

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.